In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

BACKGROUND: Combinations of drug treatments based on bortezomib or lenalidomide plus steroids have resulted in very high response rates in multiple myeloma. However, most patients still relapse, indicating the need for novel combination partners to increase duration of response or to treat relapsed...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ocio, Enrique M., Vilanova, David, Atadja, Peter, Maiso, Patricia, Crusoe, Edvan, Fernández-Lázaro, Diego, Garayoa, Mercedes, San-Segundo, Laura, Hernández-Iglesias, Teresa, de Álava, Enrique, Shao, Wenlin, Yao, Yung-Mae, Pandiella, Atanasio, San-Miguel, Jesús F.
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2010
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2864386/
https://ncbi.nlm.nih.gov/pubmed/19951978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2009.015495
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars